Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

ClinicalTrials.gov ID: NCT04723394

Public ClinicalTrials.gov record NCT04723394. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.

Study identification

NCT ID
NCT04723394
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
910 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 27, 2021
Primary completion
Aug 20, 2021
Completion
Oct 18, 2022
Last update posted
Jul 4, 2023

2021 – 2022

United States locations

U.S. sites
24
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Research Site Jasper Alabama 35501
Research Site Tucson Arizona 85704
Research Site Long Beach California 90806
Research Site Northridge California 91324
Research Site Cutler Bay Florida 33157
Research Site Miami Florida 33125
Research Site Miami Florida 33165
Research Site Pompano Beach Florida 33064
Research Site Chicago Illinois 60621
Research Site Lake Charles Louisiana 70601
Research Site St Louis Missouri 63141
Research Site La Vista Nebraska 68128
Research Site New York New York 10016
Research Site Charlotte North Carolina 28208
Research Site Charlotte North Carolina 28277
Research Site Statesville North Carolina 28625
Research Site Fargo North Dakota 58104
Research Site Columbus Ohio 43213
Research Site West Columbia South Carolina 29169
Research Site Dallas Texas 75235
Research Site Houston Texas 77027
Research Site Houston Texas 77057
Research Site Houston Texas 77093
Research Site Humble Texas 77338

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04723394, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 4, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04723394 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →